 |
 |
|
|
|
 |
|
|
|
 |
 |
|
|
-- Over 20 Targanta-Related Posters and Presentations Accepted to Meeting --
|
|
CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- Targanta Therapeutics
Corporation today announced that 23 presentations will showcase its lead
antibiotic candidate, oritavancin, and its antibiotic drug discovery platform
at the upcoming 47th Annual Interscience Conference on Antimicrobial Agents
and Chemotherapy (ICAAC), taking place in Chicago, September 17-20, 2007.
Thomas Parr, Ph.D., Chief Scientific Officer of Targanta Therapeutics
commented on the meeting: "We are very proud of the body of data being
presented on behalf of Targanta at ICAAC this year-a true testament, we
believe, to the efforts and expertise of our scientists and collaborators. We
continue to be encouraged by the breadth of data supporting the
differentiating characteristics of oritavancin and are pleased to be able to
present for the first time promising data on our pre-clinical osteomyelitis
program."
Throughout the meeting, multiple posters will highlight the in vitro
activity of oritavancin, Targanta's investigational antibiotic for the
treatment of gram-positive infections, against a wide spectrum of antibiotic
susceptible and resistant gram-positive bacteria. In addition, two
presentations at ICAAC will highlight Targanta's proprietary drug discovery
platform, which utilizes bisphosphonate prodrugs of antibiotics to generate
molecules that deliver antibiotics directly to the bone.
The following abstracts have been accepted for poster or slide
presentation at ICAAC:
| Date |
Time |
Number |
Type |
Author |
Title |
| |
| Monday, Sept. 17 |
12:00-
1:00PM
CDT |
A-49 |
Poster |
Lehoux |
PK-PD of Oritavancin (ORI) Against Streptococcus pneumoniae (SP) in a Murine-Pneumonia Infection Model |
| |
| |
|
A-50 |
Poster |
McKay |
In vitro Post Antibiotic Effect Studies of Oritavancin against Staphylococcus aureus and Enterococci |
| |
| |
|
A-51 |
Poster |
Bhavnani |
Use of Pharmacokinetic-Pharmacodynamic (PK-PD) Principles to Guide Clinical Drug Development for Oritavancin (ORI) |
| |
| |
|
D-241 |
Poster |
Tomfohrde |
Newly Defined In Vitro Quality Control Ranges for Oritavancin Broth Microdilution Testing and the Effect of Variations in Testing Conditions on MIC Results |
| |
| |
|
D-242 |
Poster |
Arhin |
Activity of Oritavancin against Drug-resistant Staphylococcus aureus in the Presence of Polysorbate-80 |
| |
| Wed., Sept. 19 |
10:00AM-
10:15AM
CDT |
B-1356 |
Slide |
Lehoux |
In Vivo Efficacy of a New Osteotropic Prodrug in a Rabbit Model of Chronic Osteomyelitis |
| |
| |
10:15AM-
10:30AM
CDT |
B-1357 |
Slide |
Tanaka |
Preparation and In vitro Evaluation of Fluoroquinolone Prodrugs for the Prevention and Treatment of Osteomyelitis |
| |
| |
11:15AM-
12:15PM
CDT |
A-1437 |
Poster |
Van Bambeke |
Comparative Intracellular Activity of 10 Antistaphylococcal Antibiotics (AABs) Against a Stable Small Colony Variant (SCV) of S. aureus in a model of human THP-1 macrophages |
| |
| |
|
C1-1471 |
Poster |
Arhin |
Mechanisms of Action of Oritavancin in Staphylococcus aureus |
| |
| |
|
C1-1472 |
Poster |
Belley |
Differential Targeting of Cell Wall Assembly Systems by Oritavancin |
| |
| |
|
C1-1473 |
Poster |
Rafai Far |
Cell-Wall Binding Sites of Desleucyl (fluorophenyl) benzylchloroeremomycin, a Damaged Oritavancin Analogue, in Staphylococcus aureus |
| |
| |
|
C1-1474 |
Poster |
Wang |
Probing the Mechanism of Inhibition of Bacterial Peptidoglycan Glycosyltransferases by Glycopeptide Analogs |
| |
| Wed., Sept. 19 |
12:15PM-
1:15PM
CDT |
C1-1474 |
Poster |
Moeck |
In Vitro Activity Profile of Oritavancin against a Broad Spectrum of Aerobic and Anaerobic Bacterial Pathogens |
| |
| |
|
E-1613 |
Poster |
Grover |
In Vitro Activity Profile of Oritavancin (ORI) against Organisms Demonstrating Key Resistance Profiles to Other Antimicrobial Agents |
| |
| |
|
E-1614 |
Poster |
McKay |
In Vitro Time Kill Studies of Oritavancin against Drug-resistant Isolates of Staphylococcus aureus and Enterococci |
| |
| |
|
E-1615 |
Poster |
Sahm |
Anti-Enterococcal Activity Profile or Oritavancin, a Potent Lipoglycopeptide under Development for Use against Gram-Positive Infections |
| |
| |
|
E-1616 |
Poster |
Draghi |
Anti-Streptococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use against Gram-Positive Infections |
| |
| |
|
E-1617 |
Poster |
Sahm |
In Vitro Activity Profile of Oritavancin against Resistant Staphylococcal Populations from a Recent Surveillance Initiative |
| |
| |
|
E-1618 |
Poster |
Wilcox |
In Vitro Susceptibility of Genotypically Distinct Clostridium difficile Strains to Oritavancin |
| |
| |
|
E-1619 |
Poster |
Belley |
Synergistic Effects of Oritavancin Tested in Combination with Other Agents |
| |
| |
|
E-1620 |
Poster |
Belley |
Pharmacokinetic Concentrations of Oritavancin Kill Stationary-Phase and Biofilm Staphylococcus aureus in Vitro |
| |
| |
|
E-1621 |
Poster |
Arhin |
Impact of Human Serum Albumin on Oritavancin In vitro Activity against Staphylococcus aureus |
| |
| |
|
E-1627a |
Poster |
Baines |
Activity of Metronidazole,Vancomycin and Oritavancin against Epidemic Clostridium difficile spores |
About Oritavancin
Oritavancin is a novel semi-synthetic lipoglycopeptide antibiotic
candidate with potent bactericidal (killing) activity against a broad spectrum
of gram-positive bacteria. The product candidate has been tested in over 1500
patients and has completed two Phase 3 studies for the treatment of
complicated skin and skin structure infection (cSSSI) in which the primary
endpoints were met. Targanta believes oritavancin's properties may give it
distinct advantages over currently marketed therapies and expects to submit a
New Drug Application to the U.S. Food and Drug Administration in the first
quarter of 2008 seeking to commercialize oritavancin for the treatment of
cSSSI.
About Targanta Therapeutics
Targanta Therapeutics Corporation is a privately held biopharmaceutical
company focused on developing and commercializing innovative antibiotics to
treat serious infections in the hospital and other institutional settings.
The Company's pipeline includes oritavancin, a semi-synthetic lipoglycopeptide
antibiotic, for which Targanta intends to seek U.S. regulatory approval in
early 2008, as well as a number of antibacterial agents in pre-clinical
development. The company has operations in Cambridge, MA, Indianapolis, IN,
Montreal, Quebec, Canada and Toronto, Ontario, Canada. For further
information about Targanta, visit the company's website at www.targanta.com.
Disclaimer
All forward-looking statements and other information included in this
press release are based on information available to Targanta as of the date
hereof, and Targanta assumes no obligation to update any such forward-looking
statements or information. Targanta's actual results could differ materially
from those described in Targanta's forward-looking statements.
SOURCE Targanta Therapeutics Corporation
-0- 09/12/2007
/CONTACT: Investors, Mark Leuchtenberger, President & Chief Executive
Officer of Targanta Therapeutics Corporation, +1-617-577-9020 x222; or
financial media, Brian Ritchie of Financial Dynamics, +1-212-850-5683, for
Targanta Therapeutics; or scientific media Annie Moore of Spectrum Science
Communications, +1-202-955-6222 x2547, for Targanta Therapeutics /
/First Call Analyst: /
/FCMN Contact: /
/Web site: http://www.targanta.com /
Source: Serenex
|
|
|
 |
|
|
|
|
|
|
|
 |
|
|
|
